BPC-157 and TB-500: What the FDA Actually Says

BPC-157 and TB-500 are two of the most discussed compounds in the recovery and performance world. They show up in podcasts, gym conversations, and social media feeds, usually attached to bold claims. This article deliberately does not repeat those claims. Instead, it lays out only what the U.S. Food and Drug Administration (FDA) has actually said, and what is a matter of public record.

The single most important fact to start with: as of this writing, neither BPC-157 nor TB-500 is approved by the FDA for any use, and the FDA has not endorsed any benefit for either compound. Anything you read describing their "benefits" is not coming from the FDA.

BPC-157 (a synthetic peptide related to a sequence found in gastric proteins) and TB-500 (a synthetic fragment of a protein called thymosin beta-4) have not gone through the FDA new-drug approval process for any medical condition. That process requires a sponsor to submit clinical trial evidence demonstrating that a drug is both safe and effective for a specific, labeled use. Neither compound has cleared it.

Because they are not approved drugs, the FDA has not published any statement of benefits, indications, or recommended dosing for them. There is no FDA-recognized use for which either compound is intended to diagnose, treat, cure, or prevent a disease.

The FDA’s most concrete public action on these compounds relates to pharmacy compounding. Under section 503A of the Federal Food, Drug & Cosmetic Act, compounding pharmacies can prepare certain medications from bulk drug substances, and the FDA maintains interim lists sorting those substances into categories while it evaluates them.

In 2023, the FDA placed BPC-157 into "Category 2" of its interim 503A bulk drug substances list — the category for substances that, in the agency’s words, raise significant safety risks. The FDA has continued to evaluate compounded peptides since then, and the regulatory status has remained unsettled rather than resolved in the compounds’ favor. The agency scheduled an advisory committee review of compounded peptides in 2026 to inform its decisions.

The takeaway is not that the FDA has praised these peptides. It is the opposite: the agency’s documented involvement has centered on safety concerns and open questions, not endorsement.

TB-500 is not FDA-approved and, as a synthetic thymosin beta-4 fragment, has not completed human efficacy trials. It is important to distinguish TB-500 from full-length thymosin beta-4, which has been studied in some clinical research settings; that research does not constitute FDA approval of TB-500 as sold in the peptide market, and the FDA has not recognized benefits for it.

A number of well-known figures in sports and fitness have discussed BPC-157 publicly. These are their own reported statements and experiences, not evidence of effectiveness and not endorsements by VitalWay:

Anyone competing under anti-doping rules should know that both BPC-157 and TB-500 are prohibited. Both appear on the World Anti-Doping Agency (WADA) Prohibited List and are banned at all times, and major leagues including the NFL and UFC prohibit them. As the Cortney Casey case illustrates, using them — even on a physician’s prescription — can result in an anti-doping violation.

BPC-157 and TB-500 are not FDA-approved, carry no FDA-recognized benefits, and — in BPC-157’s case — have been flagged by the FDA over safety concerns in the compounding context. Public statements by athletes are anecdotes, not proof of safety or effectiveness, and for competitive athletes these compounds carry real anti-doping consequences.

VitalWay makes no claims about what these compounds do. Any decision involving a prescription compound belongs in a conversation with a licensed healthcare provider who can weigh your individual situation, the current regulatory status, and the available evidence. This article is informational only and is not medical advice.